

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

General Comments and Additional Information

Test(s) 884294-LDL-P; 123475-HDL-C; 123476-Triglycerides; 123477-Cholesterol, Total; 884296-HDL-P (Total); 884297-Small LDL-P; 884309-LDL Size; 884312-LP-IR Score

was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Fasting: Yes

Total Vol:

Source:

Result Name	Flag	Result	Range/Units	Status	Lab
210475 CMP14+LP+TP+TSH+5AC+CBC/D/Pit					
Glucose	Above High Normal	102	70-99 / mg/dL	Final	01
Uric Acid		6.1	3.8-8.4 / mg/dL	Final	01
Therapeutic target for gout patients: <6.0					
BUN		15	6-24 / mg/dL	Final	01
Creatinine		1.01	0.76-1.27 / mg/dL	Final	01
eGFR		91	>59 / mL/min/1.73	Final	01
BUN/Creatinine Ratio		15	9-20	Final	01
Sodium		139	134-144 / mmol/L	Final	01
Potassium		4.5	3.5-5.2 / mmol/L	Final	01
Chloride		102	96-106 / mmol/L	Final	01
Carbon Dioxide, Total		22	20-29 / mmol/L	Final	01
Calcium		9.2	8.7-10.2 / mg/dL	Final	01
Phosphorus	Below Low Normal	2.7	2.8-4.1 / mg/dL	Final	01
Protein, Total		6.8	6.0-8.5 / g/dL	Final	01

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
Albumin		4.6	4.0-5.0 / g/dL	Final	01

****Effective July 10, 2023 Albumin reference interval****

will be changing to:

Age	Male	Female
0 - 7 days	3.6 - 4.9	3.6 - 4.9
8 - 30 days	3.5 - 4.6	3.5 - 4.6
1 - 6 months	3.7 - 4.8	3.7 - 4.8
7 months - 2 years	4.0 - 5.0	4.0 - 5.0
3 - 5 years	4.1 - 5.0	4.1 - 5.0
6 - 12 years	4.2 - 5.0	4.2 - 5.0
13 - 30 years	4.3 - 5.2	4.0 - 5.0
31 - 50 years	4.1 - 5.1	3.9 - 4.9
51 - 60 years	3.8 - 4.9	3.8 - 4.9
61 - 70 years	3.9 - 4.9	3.9 - 4.9
71 - 80 years	3.8 - 4.8	3.8 - 4.8
81 - 89 years	3.7 - 4.7	3.7 - 4.7
90 - 199 years	3.6 - 4.6	3.6 - 4.6

Globulin, Total	2.2	1.5-4.5 / g/dL	Final	01
A/G Ratio	2.1	1.2-2.2	Final	01

Patient Name:	Account Number:
Patient Phone:	
Date of Birth (Age):	Account Name:
Sex:	
Referring Dr (NPI #):	Collection Date/Time:
Patient ID:	Received Date/Time:
Specimen ID:	Reported Date/Time:

Result Name	Flag	Result	Range/Units		
Bilirubin, Total		1.1	0.0-1.2 / mg/dL	Final	01
Alkaline Phosphatase	Below Low Normal	41	44-121 / IU/L	Final	01
LDH		126	121-224 / IU/L	Final	01
AST (SGOT)		23	0-40 / IU/L	Final	01
ALT (SGPT)		15	0-44 / IU/L	Final	01
GGT		13	0-65 / IU/L	Final	01
Iron		99	38-169 / ug/dL	Final	01
Cholesterol, Total	Above High Normal	228	100-199 / mg/dL	Final	01
Triglycerides		91	0-149 / mg/dL	Final	01
HDL Cholesterol		50	>39 / mg/dL	Final	01
LDL Chol Calc (NIH)	Above High Normal	162	0-99 / mg/dL	Final	01
T. Chol/HDL Ratio		4.6	0.0-5.0 / ratio	Final	01
T. Chol/HDL Ratio					
		Men	Women		
1/2 Avg.Risk		3.4	3.3		
Avg.Risk		5.0	4.4		
2X Avg.Risk		9.6	7.1		
3X Avg.Risk		23.4	11.0		
TSH		2.030	0.450-4.500 / uIU/mL	Final	01
Thyroxine (T4)		7.2	4.5-12.0 / ug/dL	Final	01
T3 Uptake		24	24-39 / %	Final	01
Free Thyroxine Index		1.7	1.2-4.9	Final	01

Patient Name:	Account Number:
Patient Phone:	
Date of Birth (Age):	Account Name:
Sex:	
Referring Dr (NPI #):	Collection Date/Time:
Patient ID:	Received Date/Time:
Specimen ID:	Reported Date/Time:

Result Name	Flag	Result	Range/Units		
WBC		4.8	3.4-10.8 / x10E3/uL	Final	01
RBC		4.42	4.14-5.80 / x10E6/uL	Final	01
Hemoglobin		14.1	13.0-17.7 / g/dL	Final	01
Hematocrit		42.6	37.5-51.0 / %	Final	01
MCV		96	79-97 / fL	Final	01
MCH		31.9	26.6-33.0 / pg	Final	01
MCHC		33.1	31.5-35.7 / g/dL	Final	01
RDW		13.3	11.6-15.4 / %	Final	01
Platelets		203	150-450 / x10E3/uL	Final	01
Neutrophils		54	Not Estab. / %	Final	01
Lymphs		33	Not Estab. / %	Final	01
Monocytes		8	Not Estab. / %	Final	01
Eos		4	Not Estab. / %	Final	01
Basos		1	Not Estab. / %	Final	01
Neutrophils (Absolute)		2.6	1.4-7.0 / x10E3/uL	Final	01
Lymphs (Absolute)		1.6	0.7-3.1 / x10E3/uL	Final	01
Monocytes(Absolute)		0.4	0.1-0.9 / x10E3/uL	Final	01
Eos (Absolute)		0.2	0.0-0.4 / x10E3/uL	Final	01
Baso (Absolute)		0.1	0.0-0.2 / x10E3/uL	Final	01
Immature Granulocytes		0	Not Estab. / %	Final	01
Immature Grans (Abs)		0.0	0.0-0.1 / x10E3/uL	Final	01

884247 NMR LipoProfile+Lipids

LDL-P	Above High Normal	1934	<1000 / nmol/L	Final	02
-------	-------------------	------	----------------	-------	----

Low	< 1000
-----	--------

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
	Moderate	1000 - 1299			
	Borderline-High	1300 - 1599			
	High	1600 - 2000			
	Very High	> 2000			
LDL-C (NIH Calc)	Above High Normal	171	0-99 / mg/dL	Final	02
	Optimal	< 100			
	Above optimal	100 - 129			
	Borderline	130 - 159			
	High	160 - 189			
	Very high	> 189			
HDL-C		52	>39 / mg/dL	Final	02
Triglycerides		91	0-149 / mg/dL	Final	02
Cholesterol, Total	Above High Normal	239	100-199 / mg/dL	Final	02
HDL-P (Total)		31.3	>=30.5 / umol/L	Final	02
Small LDL-P	Above High Normal	816	<=527 / nmol/L	Final	02
LDL Size		21.2	>20.5 / nm	Final	02

** INTERPRETATIVE INFORMATION**

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES Percentile in Reference Population

HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7

Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839

LDL Size	<-Large (Pattern A)->	<-Small (Pattern B)->
	23.0 20.6	20.5 19.0

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

LP-IR Score	32	<=45	Final	02
-------------	----	------	-------	----

INSULIN RESISTANCE MARKER

<--Insulin Sensitive Insulin Resistant-->

Percentile in Reference Population

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

Insulin Resistance Score

LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63

LP-IR Score is inaccurate if patient is non-fasting.

The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

003772 Urinalysis, Complete

Specific Gravity		1.019	1.005-1.030	Final	01
pH	Above High Normal	8.0	5.0-7.5	Final	01
Urine-Color		Yellow	Yellow	Final	01
Appearance		Clear	Clear	Final	01
WBC Esterase		Negative	Negative	Final	01
Protein		Negative	Negative/Trace	Final	01
Glucose		Negative	Negative	Final	01
Ketones		Negative	Negative	Final	01
Occult Blood		Negative	Negative	Final	01
Bilirubin		Negative	Negative	Final	01
Urobilinogen,Semi-Qn		0.2	0.2-1.0 / mg/dL	Final	01
Nitrite, Urine		Negative	Negative	Final	01

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

Microscopic Examination

Final 01

Microscopic follows if indicated.

Microscopic Examination

See below: Final 01

Microscopic was indicated and was performed.

333328 Microscopic Examination

WBC	None seen	0 - 5 / hpf	Final	01
RBC	0-2	0 - 2 / hpf	Final	01
Epithelial Cells (non renal)	None seen	0 - 10 / hpf	Final	01
Casts	None seen	None seen / lpf	Final	01
Bacteria	None seen	None seen/Few	Final	01

001321 Iron and TIBC

Iron Bind.Cap.(TIBC)	275	250-450 / ug/dL	Final	01
UIBC	176	111-343 / ug/dL	Final	01
Iron Saturation	36	15-55 / %	Final	01

028480 FSH and LH

LH	6.1	1.7-8.6 / mIU/mL	Final	01
FSH	4.8	1.5-12.4 / mIU/mL	Final	01

140103 Testosterone,Free and Total

Testosterone	679	264-916 / ng/dL	Final	01
--------------	-----	-----------------	-------	----

Adult male reference interval is based on a population of

healthy nonobese males (BMI <30) between 19 and 39 years old.

Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

Free Testosterone(Direct)		11.8	7.2-24.0 / pg/mL	Final	02
---------------------------	--	------	------------------	-------	----

001453 Hemoglobin A1c

Hemoglobin A1c		5.4	4.8-5.6 / %	Final	01
----------------	--	-----	-------------	-------	----

Prediabetes: 5.7 - 6.4

Diabetes: >6.4

Glycemic control for adults with diabetes: <7.0

001974 Thyroxine (T4) Free, Direct

T4,Free(Direct)		1.28	0.82-1.77 / ng/dL	Final	01
-----------------	--	------	-------------------	-------	----

002014 Folate (Folic Acid), Serum

Folate (Folic Acid), Serum		13.0	>3.0 / ng/mL	Final	01
----------------------------	--	------	--------------	-------	----

A serum folate concentration of less than 3.1 ng/mL is considered to represent clinical deficiency.

004020 DHEA-Sulfate

DHEA-Sulfate		264.0	71.6-375.4 / ug/dL	Final	01
--------------	--	-------	--------------------	-------	----

004051 Cortisol

Cortisol		11.7	6.2-19.4 / ug/dL	Final	01
----------	--	------	------------------	-------	----

Please Note: The reference interval and flagging for

this test is for an AM collection. If this is a PM

collection please use: Cortisol PM: 2.3-11.9

Patient Name:	Account Number:
Patient Phone:	
Date of Birth (Age):	Account Name:
Sex:	
Referring Dr (NPI #):	Collection Date/Time:
Patient ID:	Received Date/Time:
Specimen ID:	Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

004515 Estradiol

Estradiol		27.8	7.6-42.6 / pg/mL	Final	01
Roche ECLIA methodology					

010322 Prostate-Specific Ag

Prostate Specific Ag		2.0	0.0-4.0 / ng/mL	Final	01
Roche ECLIA methodology.					

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

010363 IGF-1

Insulin-Like Growth Factor I		150	81-263 / ng/mL	Final	02
------------------------------	--	-----	----------------	-------	----

017509 Vitamin A, Serum

Vitamin A	Above High Normal	70.2	20.1-62.0 / ug/dL	Final	02
-----------	-------------------	------	-------------------	-------	----

Reference intervals for vitamin A determined from LabCorp internal

Patient Name:

Patient Phone:

Date of Birth (Age):

Sex:

Referring Dr (NPI #):

Patient ID:

Specimen ID:

Account Number:

Account Name:

Collection Date/Time:

Received Date/Time:

Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

studies. Individuals with vitamin A less than 20 ug/dL are considered vitamin A deficient and those with serum concentrations less than 10 ug/dL are considered severely deficient.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

081950 Vitamin D, 25-Hydroxy

Vitamin D, 25-Hydroxy	93.8	30.0-100.0 / ng/mL	Final	01
-----------------------	------	--------------------	-------	----

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

- IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.

Patient Name:	Account Number:
Patient Phone:	
Date of Birth (Age):	Account Name:
Sex:	
Referring Dr (NPI #):	Collection Date/Time:
Patient ID:	Received Date/Time:
Specimen ID:	Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.					
120766 C-Reactive Protein, Cardiac					
C-Reactive Protein, Cardiac		2.02	0.00-3.00 / mg/L	Final	01
Relative Risk for Future Cardiovascular Event					
Low		<1.00			
Average		1.00 - 3.00			
High		>3.00			
706994 Homocyst(e)ine					
Homocyst(e)ine		10.5	0.0-14.5 / umol/L	Final	01
001503 Vitamin B12					
Vitamin B12		1024	232-1245 / pg/mL	Final	01
004275 Growth Hormone, Serum					
Growth Hormone, Serum		0.1	0.0-10.0 / ng/mL	Final	02
004317 Progesterone					
Progesterone		0.1	0.0-0.5 / ng/mL	Final	01
010389 Triiodothyronine (T3), Free					
Triiodothyronine (T3), Free		3.9	2.0-4.4 / pg/mL	Final	01
082016 Sex Horm Binding Glob, Serum					
Sex Horm Binding Glob, Serum		34.6	19.3-76.4 / nmol/L	Final	01

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Performing Lab

01 - Labcorp Denver, 8490 Upland Drive, Englewood, CO 80112-7115, (303) 792-2600, Collum, Earle S MD

02 - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361, (800) 762-4344, Nagendra, Sanjai MD

For Inquiries, the physician may contact the performing lab.

END OF REPORT